» Articles » PMID: 27641331

Restoration of Tumor Suppression in Prostate Cancer by Targeting the E3 Ligase E6AP

Overview
Journal Oncogene
Date 2016 Sep 20
PMID 27641331
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Restoration of tumor suppression is an attractive onco-therapeutic approach. It is particularly relevant when a tumor suppressor is excessively degraded by an overactive oncogenic E3 ligase. We previously discovered that the E6-associated protein (E6AP; as classified in the human papilloma virus context) is an E3 ligase that has an important role in the cellular stress response, and it directly targets the tumor-suppressor promyelocytic leukemia protein (PML) for proteasomal degradation. In this study, we have examined the role of the E6AP-PML axis in prostate cancer (PC). We show that knockdown (KD) of E6AP expression attenuates growth of PC cell lines in vitro. We validated this finding in vivo using cell line xenografts, patient-derived xenografts and mouse genetics. We found that KD of E6AP attenuates cancer cell growth by promoting cellular senescence in vivo, which correlates with restoration of tumor suppression by PML. In addition, we show that KD of E6AP sensitizes cells to radiation-induced death. Overall, our findings demonstrate a role for E6AP in the promotion of PC and support E6AP targeting as a novel approach for PC treatment, either alone or in combination with radiation.

Citing Articles

A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.

Ganesan I, Kiyokawa H Cancers (Basel). 2025; 17(4).

PMID: 40002221 PMC: 11853300. DOI: 10.3390/cancers17040626.


E6AP is essential for the proliferation of HPV-positive cancer cells by preventing senescence.

Avenhaus A, Velimirovic M, Bulkescher J, Scheffner M, Hoppe-Seyler F, Hoppe-Seyler K PLoS Pathog. 2025; 21(2):e1012914.

PMID: 39919145 PMC: 11805377. DOI: 10.1371/journal.ppat.1012914.


High-throughput assay exploiting disorder-to-order conformational switches: application to the proteasomal Rpn10:E6AP complex.

Muli C, Tarasov S, Walters K Chem Sci. 2024; 15(11):4041-4053.

PMID: 38487241 PMC: 10935766. DOI: 10.1039/d3sc06370d.


Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts.

Thomas P, Alinezhad S, Joshi A, Sweeney K, Tse B, Tevz G Curr Oncol. 2023; 30(11):9437-9447.

PMID: 37999103 PMC: 10670201. DOI: 10.3390/curroncol30110683.


Ubiquitin-proteasome system-mediated ubiquitination modification patterns and characterization of tumor microenvironment infiltration, stemness and cellular senescence in low-grade glioma.

Gu J, Pang L, Yan D, Wang C, Song Y, Jin Z Aging (Albany NY). 2023; 15(8):2970-2998.

PMID: 37053008 PMC: 10188348. DOI: 10.18632/aging.204650.


References
1.
Srinivasan S, Nawaz Z . E3 ubiquitin protein ligase, E6-associated protein (E6-AP) regulates PI3K-Akt signaling and prostate cell growth. Biochim Biophys Acta. 2010; 1809(2):119-27. PMC: 3031754. DOI: 10.1016/j.bbagrm.2010.08.011. View

2.
Papandreou C, Logothetis C . Bortezomib as a potential treatment for prostate cancer. Cancer Res. 2004; 64(15):5036-43. DOI: 10.1158/0008-5472.CAN-03-2707. View

3.
Salomoni P, Ferguson B, Wyllie A, Rich T . New insights into the role of PML in tumour suppression. Cell Res. 2008; 18(6):622-40. DOI: 10.1038/cr.2008.58. View

4.
Hurwitz A, Foster B, Allison J, Greenberg N, Kwon E . The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol. 2008; Chapter 20:20.5.1-20.5.23. DOI: 10.1002/0471142735.im2005s45. View

5.
Wolyniec K, Chan A, Haupt S, Haupt Y . Restoring PML tumor suppression to combat cancer. Cell Cycle. 2012; 11(20):3705-6. PMC: 3495802. DOI: 10.4161/cc.22043. View